|
|
|
| home > ict > Spring 2011 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
|
 |
| |
|
|
|
|
|
Along with recent legislation, Alexander Cvetkovich-Muntañola and Kathryn Bohannon of INC Research look at the factors to consider when designing a paediatric protocol, highlighting that the many complications associated with clinical trials in children mean that sponsors should commit sufficient time to formulating a strategy before initiating such studies.
|
|
|
Consultant Stephen A Goldman examines current perspectives and approaches to pharmacovigilance planning and risk management throughout the medical product life cycle, from clinical trials through product approval to marketing.
|
|
|
Since the enforcement of the Paediatric Regulation in 2007, sponsors must now complete a paediatric investigation plan (PIP) when seeking marketing approval for unauthorised drugs or new indications. Douglas Fiebig at Trilogy Writing & Consulting puts forward the six main steps when preparing a PIP application.
|
|
|
|
|
Clinical research in Central and South American countries and the Caribbean is by no means a new phenomenon, but recent regulatory changes and political developments have caught the headlines.Maria Alejandra Espinosa and Ivana Etcheverry at Omnicare Clinical Research reacquaint us with the region, giving a breakdown of the changes by country.
|
|
|
|
|
As the clinical research associate’s role evolves to take a more hands-on approach to site management, Liz Love of Perceptive Informatics examines how eClinical solutions and clinical trial management systems will help them make their decisions easier.
|
|
|
Linda Bowers of IntraLinks discusses how software-as-a-service based solutions can be used to strengthen the relationship between investigators, as well as build various strategic partnership models between sponsors and CROs.
|
|
|
|
Douglas W Loe of Versant Partners discusses the potential of using oncolytic viruses as a form of cancer treatment, giving an update of viruses in various stages of development for a range of cancers, as well as some indicators of potential future sales earnings that can be derived from these treatments.
|
|
|
|
|
|
Data management for the pharmaceutical cold chain is a considerable challenge. Martin Peter at ELPRO-BUCHS AG Switzerland investigates the different techniques on offer for collecting this essential data, as well as how to overcome the challenges it may create.
|
|
|
|
Russ Hager of BioStorage Technologies highlights the growing role of cold chain management in supply chain processes, and emphasises the various factors that ensure on-time, compliant transportation of temperature-sensitive clinical trial materials and supplies.
|
|
|
|
|
|
In spite of how ‘old’ the pharma industry is, there is still a lack of industry-adopted clinical trial performance metrics.However,well-defined standards are needed to provide the fundamental tools for running efficient, effective clinical trials, explains Linda Buchin Sullivan of the Metrics Champion Consortium (MCC).
|
|
|
Nick Jackson at i3 presents both a customer’s and a CRO’s perspective on using the MCC metrics, and discusses the role of the Process Improvement Work Group.
|
|
|
|
|
Like any other business, pharmaceuticals need performance indicators to measure business success, but unlike any other business, the industry has a unique model. So, how do you pilot a business that is like no other? Dimitri Stamatiadis at Merck Serono suggests that a balanced scorecard might be the answer.
|
|
|
|
Company stakeholders frequently view quality assurance as a ‘nice to have’, and are not always aware of its full impact on the organisation if it is not taken seriously. Nicky Dodsworth and Sherri Hubby at Premier Research Group Ltd stress that in the struggle for survival in today’s regulatory environment, quality assurance must take a more active role.
|
|
|
As with every other aspect of life, clinical research companies must ensure they have appropriate insurance for their activities.However, they cannot afford for this protection to hinder speed-to-market efforts. As a result, there is a need for web-based technologies to make the process more efficient and transparent, explains Kathleen Burns of Aon eSolutions.
|
|
|
|
|
For an industry boasting excellence and the use of cutting-edge technology in all aspects of its operation, the pharma world is only just beginning to regard the role clinical events with the same importance as other parts of a study. Andy Thurstan at MD Events considers best practices for planning and delivering outstanding meetings.
|
|
|
It is vital that clinical research organisations have well-trained employees who are equipped to operate at the highest standard.Gerald Van Roey at the European Centre for Clinical Research Training gives some tips for designing a strong staff development programme.
|
|
|
Many organisations are trying to find ways to cut their budgets, and often one of the first casualties is training. However, developing a strong coaching culture in an organisation can prove to be a cost-effective measure in the long term, explains Martin Robinson of Dovetail Clinical.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Headlands Research Acquires Established Eastern Massachusetts–Based Research Site Specializing in Neurodegenerative Diseases
San Francisco, CA, April 18, 2023 — Headlands Research,
a leading multinational network of clinical trial sites, today
announced the acquisition of an established clinical research site, now
known as Headlands Research Eastern Massachusetts. The site has
specialized in neurodegenerative diseases such as Alzheimer’s disease
and Parkinson’s disease for over 25 years.
More info >> |
|
 |
White Papers |
 |
|
Device Develop for Combo Products
Phillips-Medisize
Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >> |
|
|
